Peptide Vaccines Raise Concern in Animal Study
Posted on: Friday, 27 January 2006, 17:15 CST
By David Douglas
NEW YORK (Reuters Health) - Findings from an animal study indicate that inoculation with so-called peptide vaccines can have lethal consequences.
A peptide vaccine contains small synthetic proteins designed to activate the immune system against a particular virus or other microbe. In particular, they work by stimulating the body's "killer" T cells to go out and destroy the invading pathogen. Unfortunately, in this study, the T cells appeared to go over-board and killed the animal too.
Synthetic peptides "are considered promising candidates for new-generation vaccines," senior investigator Dr. J. Lindsay Whitton, from Scripps Research Institute, La Jolla, California told Reuters Health. However, "our findings show that peptide vaccines can be harmful, especially if improperly formulated or delivered."
In the study, virus-infected mice that received a peptide vaccine experienced a rapid and severe drop in body temperature. Some of the animals, infected with a virus called LCMV, died within hours of vaccination. As noted, the researchers blamed the deaths not on the virus per se, but on the vigorous and overwhelming killer T cell response.
Despite these findings, the researchers do not believe that peptide vaccines should be abandoned. "Although our results raise a cautionary flag, they should not be taken as an indication that the peptide vaccine approach is fatally flawed," Whitton emphasized.
SOURCE: Journal of Clinical Investigation, February 2006.
Source: REUTERS
Related Articles
- Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
- Merck's Investigational HIV Vaccine Fails in Study
- CollaGenex Pharmaceuticals Announces Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Rosacea
- CollaGenex Pharmaceuticals Announces Positive Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Acne
- Pre-Clinical Study of Novavax's Seasonal Influenza Vaccine Published in Journal 'Vaccine'
- FDA Approves Expanded Age Indication for VAQTA(R) (Hepatitis A Vaccine, Inactivated), Merck's Hepatitis A Vaccine, to Children As Young As 12 Months of Age
- Field Evaluation of Flock Production Performance of In Ovo Injection of Infectious Bursal Disease Virus Immune Complex Vaccine in Commercial Broiler Farms
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
- Study Finds Cholera Vaccine Effective
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Adults With Primary Sleep Maintenance Insomnia
 |
 |
User Comments (0)
RSS Feeds